Search Results 81-90 of 24220 for B cell lymphomas

  1. Chronic lymphocytic leukemia - Symptoms and causes - Mayo Clinic

    Monoclonal B-cell lymphocytosis (MBL) causes an increased number of a type of lymphocyte, called B lymphocytes, in the blood. ... B-cell lymphoma. This is ...

  2. Phase 2 Study with TTI-622 and TTI-621 in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) - Mayo Clinic

    T-cell/histiocyte-rich large B cell lymphoma. Large B-cell lymphoma with ... FDG-nonavid lymphomas: Measurable disease with CT (or MRI) scan with ...

  3. DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Relapse in Aggressive B-cell Non-Hodgkin Lymphomas - Mayo Clinic

    DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Relapse in Aggressive B-cell Non-Hodgkin Lymphomas · Overview · Participation eligibility.

  4. Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus RCHOP in Participants with Previously Untreated High-risk Large B-cell Lymphoma - Mayo Clinic

    Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus RCHOP in Participants with Previously Untreated High-risk Large B-cell Lymphoma.

  5. CAR-T cell therapy - Mayo Clinic

    Lymphomas are cancers that affect white blood cells in the lymphatic system — a network of organs, glands, vessels and clusters of cells called lymph nodes. B- ...

  6. Science Saturday: Quest to unmask an elusive immune cancer - Mayo Clinic News Network

    Among non-Hodgkin lymphomas, the most common is diffuse large B-cell lymphoma, which represents about 30 percent of all lymphomas in the U.S.. Committed to ...

  7. A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma - Mayo Clinic

    CD20+Diffuse Large B-Cell Lymphoma. · Ann Arbor stage 3 or 4 or stage 2 with bulky disease · High or high-intermediate disease risk. · No prior anti-lymphoma ...

  8. Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma - Mayo Clinic

    Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma · Overview · Participation eligibility.

  9. Study of BMF-219, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) - Mayo Clinic

    ... B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL). Print details. Share; Facebook ...

  10. A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants - Mayo Clinic

    ... Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants. Print details. Share; Facebook · Twitter. Overview ...